Regeneron Pharmaceuticals, Inc. $REGN Stock: Robeco Institutional Asset Management B.V. Trims Stake

Robeco Institutional Asset Management B.V. lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 402,958 shares of the biopharmaceutical company’s stock after selling 57,644 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Regeneron Pharmaceuticals were worth $305,551,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. LCM Capital Management Inc raised its stake in shares of Regeneron Pharmaceuticals by 2.2% in the third quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after purchasing an additional 13 shares in the last quarter. Arjuna Capital lifted its position in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 14 shares during the period. Boyd Watterson Asset Management LLC OH boosted its stake in Regeneron Pharmaceuticals by 1.4% during the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 15 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in Regeneron Pharmaceuticals by 1.8% during the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock worth $645,000 after buying an additional 15 shares in the last quarter. Finally, Aaron Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 1.5% in the 1st quarter. Aaron Wealth Advisors LLC now owns 1,102 shares of the biopharmaceutical company’s stock valued at $851,000 after buying an additional 16 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 3.3%

Shares of REGN stock opened at $807.48 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $572.75 and a 12-month high of $859.34. The company has a market capitalization of $83.14 billion, a P/E ratio of 19.96, a P/E/G ratio of 1.35 and a beta of 0.16. The firm has a 50-day moving average price of $791.41 and a 200 day moving average price of $721.87. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business earned $12.81 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.98 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on REGN. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. Cantor Fitzgerald lifted their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Royal Bank Of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a “sector perform” rating in a research report on Thursday, October 8th. Sanford C. Bernstein upped their target price on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a research note on Friday, August 14th. Finally, Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $845.59.

Insider Activity

In other news, insider Andrew Murphy sold 4,147 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.